<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02032368</url>
  </required_header>
  <id_info>
    <org_study_id>CTCtrial001</org_study_id>
    <nct_id>NCT02032368</nct_id>
  </id_info>
  <brief_title>Decrease in Circulating Tumour Cell Count Reflects the Effectiveness of Postoperative Adjuvant Transarterial Chemoembolization (TACE) in Preventing Hepatocellular Carcinoma Recurrence</brief_title>
  <official_title>Decrease in Circulating Tumour Cell Count Reflects the Effectiveness of Postoperative Adjuvant Transarterial Chemoembolization (TACE) in Preventing Hepatocellular Carcinoma Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Circulating tumour cell (CTC) count could reflect the effect of postoperative transarterial
      chemoembolization (TACE) on hepatocellular carcinoma (HCC) recurrence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early metastases of hepatocellular carcinoma (HCC) may be detected by the isolation of
      circulating tumor cells (CTCs) in the bloodstream. During the course of therapeutic attempts,
      monitoring CTC changes in patients with HCC is helpful for the efficacy assessment.
      Nevertheless, the markers used for the detection, such as a-feto protein, asialoglycoprotein
      receptor or epithelial cell adhesion molecule, CD133 or CD90, are not specific for HCC CTCs.
      In spite of these limitations, a timely determination of the existence of CTCs will be
      beneficial for the monitoring of distant metastases, the evaluation of therapeutic attempts,
      and the prediction of prognosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of circulating tumor cell(CTC) count at different timepoints</measure>
    <time_frame>time before TACE and time after TACE</time_frame>
    <description>The time points for blood collection to count CTC were1)one day before TACE(also one month after resection);2)three days after TACE;3)one month after TACE;4) two months after TACE;5)three months after TACE;6)six months after TACE;7) one year after TACE.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Circulating Tumor Cell;</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>TACE group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in TACE group receive transarterial chemoembolization (TACE) one month after resection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in Control group receive no management.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transarterial chemoembolization (TACE)</intervention_name>
    <arm_group_label>TACE group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  definitive pathological diagnosis of HCC based on World Health Organization (WHO)
             criteria;

          -  underwent curative resection one month ago, CT or MRI detecting no new lesions when
             recruited;

          -  CTC counts≥2 after resection;

          -  age between 18 and 75 years;

          -  adequate hematologic function (platelet count: &gt;60 × 109 platelets/L; hemoglobin:
             &gt;90g/L; and prothrombin time: &lt;3 seconds above control);

          -  adequate renal function (serum creatinine: ≤1.5 × upper limit of normal);

          -  Child-Pugh classification A or B grade

        Exclusion Criteria:

          -  a hypovascular tumor (defined as a tumor with all its parts less contrast-enhanced
             than the nontumorous liver parenchyma on arterial phase computed tomography scans);

          -  diffuse-type HCC;

          -  evidence of hepatic decompensation including esophageal or gastric variceal bleeding
             or hepatic encephalopathy;

          -  severe underlying cardiac or renal diseases;

          -  color Doppler ultrasonography showing portal vein tumor thrombosis with complete main
             portal vein obstruction without cavernous transformation;

          -  obstructive jaundice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Interventional Radiology; Cancer Center; Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2014</study_first_submitted>
  <study_first_submitted_qc>January 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2014</study_first_posted>
  <last_update_submitted>January 8, 2014</last_update_submitted>
  <last_update_submitted_qc>January 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>circulating tumour cell;</keyword>
  <keyword>transarterial chemoembolization;</keyword>
  <keyword>hepatocellular carcinoma;</keyword>
  <keyword>recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

